A Phase 1 Three Period Crossover Study Evaluating the Relative Oral Bioavailability of New Formulations of ABT-263 in Healthy Female Subjects.
Phase of Trial: Phase I
Latest Information Update: 26 Nov 2014
At a glance
- Drugs Navitoclax (Primary)
- Indications Chronic lymphocytic leukaemia; Lymphoid leukaemia; Lymphoma; Small cell lung cancer
- Focus Pharmacokinetics
- Sponsors Abbott Laboratories
- 19 Feb 2010 Actual end date (Jan 2010) added as reported by ClinicalTrials.gov.
- 19 Feb 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 28 Jan 2010 New trial record